All phar­ma com­pa­nies in the first round of Medicare price ne­go­ti­a­tions agree to par­tic­i­pate

All com­pa­nies with drugs on CMS’ list for the first round of Medicare price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act have agreed to par­tic­i­pate as of this morn­ing, the dead­line by which com­pa­nies had to sub­mit new drug da­ta to CMS.

John­son & John­son, Am­gen and No­var­tis have all signed ne­go­ti­a­tion agree­ments ahead of the Oct. 1 dead­line, they told End­points News on Mon­day. No­vo Nordisk al­so agreed to par­tic­i­pate, End­points learned on Sun­day. Mer­ck, Boehringer In­gel­heim, Bris­tol My­ers Squibb and As­traZeneca pre­vi­ous­ly an­nounced their in­ten­tions to agree to the ne­go­ti­a­tions. Com­pa­nies that do not com­ply would face a heavy tax or risk los­ing out on Medicare and Med­ic­aid cov­er­age al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER